Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Net Margin (2016 - 2025)

CorMedix's Net Margin history spans 14 years, with the latest figure at 9.16% for Q4 2025.

  • For Q4 2025, Net Margin fell 4927.0% year-over-year to 9.16%; the TTM value through Dec 2025 reached 44.19%, up 8845.0%, while the annual FY2025 figure was 44.03%, 8468.0% up from the prior year.
  • Net Margin for Q4 2025 was 9.16% at CorMedix, down from 104.08% in the prior quarter.
  • Across five years, Net Margin topped out at 215775.76% in Q2 2024 and bottomed at 100538.67% in Q3 2022.
  • The 5-year median for Net Margin is 104.08% (2025), against an average of 32498.79%.
  • The largest annual shift saw Net Margin soared 8351341bps in 2022 before it crashed -21572455bps in 2025.
  • A 5-year view of Net Margin shows it stood at 17141.59% in 2021, then plummeted by -61bps to 27656.38% in 2022, then surged by 535bps to 120410.51% in 2023, then crashed by -100bps to 40.11% in 2024, then plummeted by -123bps to 9.16% in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Net Margin are 9.16% (Q4 2025), 104.08% (Q3 2025), and 51.21% (Q2 2025).